Company / Capital Expenditures
Arbutus Biopharma Corp Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
-
FY2025
5-year range
$0 / $1.0M
FY2021-FY2025
Trend
-100.0%
vs FY2024
Sector context
#190 of 194
Health Care
What the data says
Declined from $1M to $0 over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 2% in Health CareTop 98% of 194
▼
Key checks
Key Insights
- In FY2025, capital expenditures decreased 100.0% year-over-year.
- Peak capital expenditures was recorded in FY2018.
Company context
Key Data Points
- Altman Z-Score -11.01 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0 | -100.0% |
| FY2024 | $182.0K | -81.9% |
| FY2023 | $1.0M | +96.9% |
| FY2022 | $512.0K | -36.7% |
| FY2021 | $809.0K | +37.4% |
| FY2020 | $589.0K | -48.2% |
| FY2019 | $1.1M | -84.3% |
| FY2018 | $7.3M | +0.0% |
| FY2017 | $7.3M | +81.8% |
| FY2016 | $4.0M | +74.7% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026